Genitourinary Cancers

David F. McDermott MD and Daniel P. Petrylak MD review data from key genitourinary cancer presentations from the 2015 clinical oncology meeting in Chicago.

Share

Program Content

Activities

  • Biomarkers for Nivolumab in mRCC
    Predictive Biomarkers and Nivolumab Activity in mRCC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 04, 2015

    Expires: June 02, 2016

  • Apatorsen in Bladder Ca
    Borealis-1: Apatorsen + Gemcitabine/Cisplatin for Pts With Advanced Bladder Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 04, 2015

    Expires: June 02, 2016

  • Eribulin in Urothelial Cancer
    NCI/CTEP 7435: Eribulin Active, Tolerable in Urothelial Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 04, 2015

    Expires: June 02, 2016

  • Maintenance Lapatinib in UBC
    Maintenance Lapatinib After Chemotherapy in HER1/2-Positive Metastatic Bladder Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 04, 2015

    Expires: June 02, 2016

  • Sunitinib, Everolimus in NCRCC
    ASPEN: Prolonged PFS With Sunitinib vs Everolimus in Nonclear-Cell RCC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 04, 2015

    Expires: June 02, 2016

  • ASSURE: Dose Analysis
    ASSURE: Dose Reduction of Sunitinib or Sorafenib Not Associated With Improved Outcomes in Resected RCC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 04, 2015

    Expires: June 02, 2016

  • mTOR Mutations in RCC
    Mutations Predict Responses to mTOR Inhibitors in mRCC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 04, 2015

    Expires: June 02, 2016

  • SYNERGY Reanalysis
    SYNERGY: Custirsen in Poor-Prognosis mCRPC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 05, 2015

    Expires: June 03, 2016

  • Atezolizumab in UBC
    Atezolizumab (MPDL3280A) Shows Favorable Tolerability, Promising Activity in Urothelial Bladder Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 05, 2015

    Expires: June 03, 2016

  • KEYNOTE-012: Pembrolizumab
    KEYNOTE-012: Pembrolizumab Shows Promising Antitumor Activity and Safety in Advanced Urothelial Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 05, 2015

    Expires: June 03, 2016

  • Docetaxel in Prostate Cancer
    STAMPEDE: Docetaxel Significantly Improves Survival in Men With Hormone-Naive Prostate Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 05, 2015

    Expires: June 03, 2016

  • mCRPC: Histologic Subtypes
    Intermediate Atypical Carcinoma: Novel Histological Subtype of mCRPC in Patients Resistant to Androgen Receptor Agonists
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 05, 2015

    Expires: June 03, 2016

  • Downloadable Slideset
    Genitourinary Cancers
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 20, 2015

    Expires: August 18, 2016

  • Lenvatinib ± Everolimus in mRCC
    Improved Survival and Response With Lenvatinib ± Everolimus vs Everolimus Alone in Metastatic RCC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

Provided by

ProCE Banner

Supporters

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Celgene

Genentech BioOncology

Incyte

Novartis Pharmaceuticals Corporation